Condition
Immune Mediated Inflammatory Diseases
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Bay1830839
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Phase 1 (2)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT07499908Phase 1Completed
Trial in Healthy Volunteers to Evaluate 150 mg Subcutaneous CIT-013
NCT05003089Phase 1CompletedPrimary
A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male Participants
Showing all 2 trials
Research Network
Common Treatments
- Bay18308391
- Prednisolone1
- Cit013 High Dose1
- Bay18348451
Active Sponsors
- Bayer1
- Citryll BV1
Top Investigators
Citryll BV
Related Conditions
- Healthy Adult1